Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 75/100

Termination Rate

16.7%

1 terminated out of 6 trials

Success Rate

0.0%

-86.5% vs benchmark

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

0

Data Visualizations

Phase Distribution

4Total
Not Applicable (2)
P 2 (1)
P 4 (1)

Trial Status

Recruiting2
Unknown1
Not Yet Recruiting1
Terminated1
Withdrawn1

Clinical Trials (6)

Showing 6 of 6 trials
NCT06145802Not ApplicableWithdrawn

Clinical Study of Autologous Tumor Infiltrating Lymphocyte Injection (GT316) in the Treatment of Advanced Solid Tumors (Gynecological Tumors)

NCT06191900Not ApplicableTerminated

Clinical Study of GT201 in the Treatment of Advanced Gynecological Tumors (Advanced Cervical Cancer)

NCT07259681Not Yet Recruiting

Gut Microbiome in Gynecological Cancer Patients With Pelvic Toxicity: Controls Versus Ozone Treatment. (MicrOzoGineTox)

NCT06798207Phase 2RecruitingPrimary

A Clinical Trial of TQB2102 for Injection in Gynecological Tumors With Recurrent/Metastatic Advanced

NCT06159907RecruitingPrimary

Evaluation of the Diagnostic and Prognostic Role of PET (PET/CT and PET/MRI) in Gynecological Tumors.

NCT02905916Phase 4Unknown

The Efficacy and Safety of PEG-rhG-CSF in Neutropenia After Chemotherapy

Showing all 6 trials

Research Network

Activity Timeline